Literature DB >> 26091716

CD56brightCD16- NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation.

Fabio Morandi1, Alberto L Horenstein2, Antonella Chillemi3, Valeria Quarona3, Sabrina Chiesa4, Andrea Imperatori5, Silvia Zanellato6, Lorenzo Mortara7, Marco Gattorno4, Vito Pistoia8, Fabio Malavasi2.   

Abstract

Recent studies suggested that human CD56(bright)CD16(-) NK cells may play a role in the regulation of the immune response. Since the mechanism(s) involved have not yet been elucidated, in the present study we have investigated the role of nucleotide-metabolizing enzymes that regulate the extracellular balance of nucleotides/nucleosides and produce the immunosuppressive molecule adenosine (ADO). Peripheral blood CD56(dim)CD16(+) and CD56(bright)CD16(-) NK cells expressed similar levels of CD38. CD39, CD73, and CD157 expression was higher in CD56(bright)CD16(-) than in CD56(dim)CD16(+) NK cells. CD57 was mostly expressed by CD56(dim)CD16(+) NK cells. CD203a/PC-1 expression was restricted to CD56(bright)CD16(-) NK cells. CD56(bright)CD16(-) NK cells produce ADO and inhibit autologous CD4(+) T cell proliferation. Such inhibition was 1) reverted pretreating CD56(bright)CD16(-) NK cells with a CD38 inhibitor and 2) increased pretreating CD56(bright)CD16(-) NK cells with a nucleoside transporter inhibitor, which increase extracellular ADO concentration. CD56(bright)CD16(-) NK cells isolated from the synovial fluid of juvenile idiopathic arthritis patients failed to inhibit autologous CD4(+) T cell proliferation. Such functional impairment could be related to 1) the observed reduced CD38/CD73 expression, 2) a peculiar ADO production kinetics, and 3) a different expression of ADO receptors. In contrast, CD56(bright)CD16(-) NK cells isolated from inflammatory pleural effusions display a potent regulatory activity. In conclusion, CD56(bright)CD16(-) NK cells act as "regulatory cells" through ADO produced by an ectoenzymes network, with a pivotal role of CD38. This function may be relevant for the modulation of the immune response in physiological and pathological conditions, and it could be impaired during autoimmune/inflammatory diseases.
Copyright © 2015 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26091716     DOI: 10.4049/jimmunol.1500591

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

1.  CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment.

Authors:  Shi Yong Neo; Ying Yang; Julien Record; Ran Ma; Xinsong Chen; Ziqing Chen; Nicholas P Tobin; Emily Blake; Christina Seitz; Ron Thomas; Arnika Kathleen Wagner; John Andersson; Jana de Boniface; Jonas Bergh; Shannon Murray; Evren Alici; Richard Childs; Martin Johansson; Lisa S Westerberg; Felix Haglund; Johan Hartman; Andreas Lundqvist
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 2.  Adenosinergic signaling as a target for natural killer cell immunotherapy.

Authors:  Jiao Wang; Sandro Matosevic
Journal:  J Mol Med (Berl)       Date:  2018-08-01       Impact factor: 4.599

Review 3.  Adenosine production: a common path for mesenchymal stem-cell and regulatory T-cell-mediated immunosuppression.

Authors:  Martha de Oliveira Bravo; Juliana Lott Carvalho; Felipe Saldanha-Araujo
Journal:  Purinergic Signal       Date:  2016-08-25       Impact factor: 3.765

4.  Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma.

Authors:  Alberto L Horenstein; Valeria Quarona; Denise Toscani; Federica Costa; Antonella Chillemi; Vito Pistoia; Nicola Giuliani; Fabio Malavasi
Journal:  Mol Med       Date:  2016-10-13       Impact factor: 6.354

Review 5.  The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets.

Authors:  Bertrand Allard; Maria Serena Longhi; Simon C Robson; John Stagg
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

6.  Chemoenzymatic Preparation of 4'-Thioribose NAD.

Authors:  Xiao-Nan Zhang; Zhefu Dai; Qinqin Cheng; Yong Zhang
Journal:  Curr Protoc Nucleic Acid Chem       Date:  2019-04-05

7.  Altered populations of natural killer cells, cytotoxic T lymphocytes, and regulatory T cells in major depressive disorder: Association with sleep disturbance.

Authors:  Hideo Suzuki; Jonathan Savitz; T Kent Teague; Siva K Gandhapudi; Chibing Tan; Masaya Misaki; Brett A McKinney; Michael R Irwin; Wayne C Drevets; Jerzy Bodurka
Journal:  Brain Behav Immun       Date:  2017-06-20       Impact factor: 7.217

8.  CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.

Authors:  Limo Chen; Lixia Diao; Yongbin Yang; Xiaohui Yi; B Leticia Rodriguez; Yanli Li; Pamela A Villalobos; Tina Cascone; Xi Liu; Lin Tan; Philip L Lorenzi; Anfei Huang; Qiang Zhao; Di Peng; Jared J Fradette; David H Peng; Christin Ungewiss; Jonathon Roybal; Pan Tong; Junna Oba; Ferdinandos Skoulidis; Weiyi Peng; Brett W Carter; Carl M Gay; Youhong Fan; Caleb A Class; Jingfen Zhu; Jaime Rodriguez-Canales; Masanori Kawakami; Lauren Averett Byers; Scott E Woodman; Vassiliki A Papadimitrakopoulou; Ethan Dmitrovsky; Jing Wang; Stephen E Ullrich; Ignacio I Wistuba; John V Heymach; F Xiao-Feng Qin; Don L Gibbons
Journal:  Cancer Discov       Date:  2018-07-16       Impact factor: 39.397

9.  Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.

Authors:  Jakub Krejcik; Kris A Frerichs; Inger S Nijhof; Berris van Kessel; Jeroen F van Velzen; Andries C Bloem; Marloes E C Broekmans; Sonja Zweegman; Johan van Meerloo; René J P Musters; Pino J Poddighe; Richard W J Groen; Christopher Chiu; Torben Plesner; Henk M Lokhorst; A Kate Sasser; Tuna Mutis; Niels W C J van de Donk
Journal:  Clin Cancer Res       Date:  2017-10-12       Impact factor: 12.531

10.  Human natural killer cells mediate adaptive immunity to viral antigens.

Authors:  Rana Nikzad; Laura S Angelo; Kevin Aviles-Padilla; Duy T Le; Vipul K Singh; Lynn Bimler; Milica Vukmanovic-Stejic; Elena Vendrame; Thanmayi Ranganath; Laura Simpson; Nancy L Haigwood; Catherine A Blish; Arne N Akbar; Silke Paust
Journal:  Sci Immunol       Date:  2019-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.